In an effort to develop a successful CRAd geared toward the treatment of disseminated ovarian cancer, we proposed that arming it with TIMP2 would augment the therapeutic efficacy of the CRAd by inhibiting tumor progression through both MMP-dependent and MMP-independent pathways. The gene discussed is TIMP2; the disease is ovarian carcinoma.